Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nkgen Biotech Inc (NKGN)

Nkgen Biotech Inc (NKGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 6,219
  • Shares Outstanding, K 124,377
  • Annual Sales, $ 0 K
  • Annual Income, $ -44,290 K
  • EBIT $ -27 M
  • EBITDA $ -26 M
  • 60-Month Beta 0.98
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.72
  • Most Recent Earnings $-0.95 on 10/07/25
  • Next Earnings Date 03/03/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0310 +61.29%
on 11/25/25
0.0600 -16.67%
on 12/18/25
+0.0290 (+138.10%)
since 11/20/25
3-Month
0.0002 +24,900.00%
on 10/06/25
0.3299 -84.84%
on 10/13/25
-0.0600 (-54.55%)
since 09/22/25
52-Week
0.0002 +24,900.00%
on 10/06/25
0.9649 -94.82%
on 12/26/24
-0.5900 (-92.19%)
since 12/20/24

Most Recent Stories

More News
NKGen Biotech, Inc. Issues Statement on Recent Board Appointments at Majority-Owned Korean Affiliate NKGen Korea Co., Ltd.

SANTA ANA, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization...

NKGN : 0.0500 (unch)
NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market

SANTA ANA, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization...

NKGN : 0.0500 (unch)
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology

SANTA ANA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization...

NKGN : 0.0500 (unch)
NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum

SANTA ANA, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization...

NKGN : 0.0500 (unch)
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets

NKGen acquires controlling stake in NKMax, marking a pivotal moment in its transformation into a fully integrated, self-sustaining, cell therapy company with global manufacturing and IP control. Approximately...

NKGN : 0.0500 (unch)
NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit

SANTA ANA, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization...

NKGN : 0.0500 (unch)
NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer’s Association International Conference 2025

Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration....

NKGN : 0.0500 (unch)
NKGen Biotech to Present at the Alzheimer’s Association International Conference 2025

SANTA ANA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization...

NKGN : 0.0500 (unch)
NKGen Receives FDA Expanded Access Protocol Authorization for Landmark Treatment of Several Neurodegenerative Diseases

Troculeucel, a cryopreserved, autologous enhanced natural killer cell therapy, has demonstrated preliminary clinical benefit without any drug-related adverse events in two Phase I clinical trials in Alzheimer’s...

NKGN : 0.0500 (unch)
NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan

In connection with HekaBio’s recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial development of NKGen’s autologous NK cell...

NKGN : 0.0500 (unch)

Business Summary

NKGen Biotech Inc. is a clinical-stage biotechnology company. It focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies. NKGen Biotech Inc., formerly known as Graf Acquisition Corp. IV, is based in THE WOODLANDS, Texas.

See More

Key Turning Points

3rd Resistance Point 0.0500
2nd Resistance Point 0.0500
1st Resistance Point 0.0500
Last Price 0.0500
1st Support Level 0.0500
2nd Support Level 0.0500
3rd Support Level 0.0500

See More

52-Week High 0.9649
Fibonacci 61.8% 0.5964
Fibonacci 50% 0.4825
Fibonacci 38.2% 0.3687
Last Price 0.0500
52-Week Low 0.0002

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar